Skip to main content
GutCited

Long-term treatment with probiotics in primary care patients with irritable bowel syndrome--a randomised, double-blind, placebo controlled trial.

Luise Mølenberg Begtrup, Ove B Schaffalitzky de Muckadell, Jens Kjeldsen, René Depont Christensen, Dorte Ejg Jarbøl
RCT Scandinavian journal of gastroenterology 2013 74 citations

Study Design

Study Type
Randomized Controlled Trial
Population
Primary care IBS patients (Rome III criteria)
Duration
24 weeks
Intervention
Long-term treatment with probiotics in primary care patients with irritable bowel syndrome--a randomised, double-blind, placebo controlled trial.
Comparator
Placebo
Primary Outcome
IBS symptoms (Rome III criteria) over 6 months
Effect Direction
Neutral
Risk of Bias
Low

Abstract

OBJECTIVE. Meta-analyses have indicated effect of probiotics on irritable bowel syndrome (IBS). However, few long-term trials have been conducted and uncertainty remains as to effectiveness and long-term effect in a primary care setting. We aimed to investigate the effect of probiotics compared with placebo in the management of IBS in primary care during a 6-month treatment period and with a 6-month follow-up. MATERIAL AND METHODS. We randomized IBS patients fulfilling Rome III criteria to receive two capsules twice daily either containing placebo or a probiotic mixture of Lactobacillus paracasei ssp paracasei F19, Lactobacillus acidophilus La5 and Bifidobacterium Bb12 in an amount of 1.3 × 10(10) CFU per capsule. Primary endpoint was proportion of responders defined as patients reporting adequate relief (AR) at least 50% of the time in the 6-month treatment period. Secondary outcomes were proportions of patients reporting AR at different time points, and change in gastrointestinal symptoms and health-related quality of life (HrQOL) from baseline to 6 and 12 months. RESULTS. A total of 131 patients were included in this study. The proportion of responders in the treatment period was 52% (35/67) in the probiotic group versus 41% (26/64) in the placebo group, p = 0.18. Overall we found no difference between the groups in change in gastrointestinal symptoms after treatment. Patients improved in HrQOL, but with no statistically significant difference between the groups. CONCLUSION. During a 6-month treatment period, we were not able to detect a positive effect of probiotic when compared with placebo.

TL;DR

During a 6-month treatment period, it was not able to detect a positive effect of probiotic when compared with placebo, and patients improved in HrQOL, but with no statistically significant difference between the groups.

Used In Evidence Reviews

Similar Papers

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.